<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591277</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-1498</org_study_id>
    <nct_id>NCT02591277</nct_id>
  </id_info>
  <brief_title>Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection</brief_title>
  <official_title>A Prospective Observational Post-Marketing Study of Harvoni in Japanese Patients With Genotype 1 Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of Harvoni® (ledipasvir/sofosbuvir
      (LDV/SOF) fixed-dose combination (FDC)) treatment under real world use in Japan. Among adult
      patients with chronic genotype 1 hepatitis C virus (HCV) infection and treated with Harvoni
      in routine clinical use, the primary objective of this study is to evaluate the incidence of
      adverse drug reactions (ADRs) under real world settings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of adverse drug reaction (ADR) under real world settings</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 12 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 and SVR24 are defined as HCV RNA &lt; the lower limit of quantification (LLOQ) 12 and 24 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HCV NS5A and NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks</measure>
    <time_frame>Approximately 12 weeks after treatment completion or discontinuation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Harvoni</arm_group_label>
    <description>Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Harvoni</intervention_name>
    <description>Harvoni (90/400 mg) FDC tablet administered orally once daily</description>
    <arm_group_label>Harvoni</arm_group_label>
    <other_name>LDV/SOF</other_name>
    <other_name>GS-5885/GS-7977</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis
        who take Harvoni as part of routine clinical care at a participating clinic/hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with chronic genotype 1 HCV infection with or without compensated
             cirrhosis

          -  Patients who are prescribed Harvoni

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Ng, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>JP.HCV.PMS@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Asahi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chichibu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujioka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashiibaraki-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Iruma-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 8, 2015</lastchanged_date>
  <firstreceived_date>October 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>observational</keyword>
  <keyword>post-marketing</keyword>
  <keyword>ledipasvir/sofosbuvir</keyword>
  <keyword>Japan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
